Castle Biosciences’ DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures
Castle Biosciences, Inc.’s DecisionDx-Melanoma test can accurately identify patients with a low risk of metastasis who can safely forgo sentinel lymph node biopsy (SLNB), thereby reducing unnecessary SLNB procedures and the associated costs and risks of complications that accompany them. The data was presented in a poster and oral presentation at The European Congress on […]